PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer/T cell lymphoma

BACKGROUND: PARP inhibitor (PARPi), as a kind of DNA damage repair inhibitor, has been shown to be effective in various solid tumors and hematologic malignancies. Natural killer/T cell lymphoma (NKTCL) is a highly aggressive malignancy, the treatment of which has long been a major challenge in the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jiazhuo, Shi, Cunzhen, Li, Hongwen, Song, Wenting, Huang, Shuo, Zhang, Jianxiang, Li, Wencai, Li, Zhaoming, Zhang, Mingzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347840/
https://www.ncbi.nlm.nih.gov/pubmed/37442994
http://dx.doi.org/10.1186/s12916-023-02904-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347840/
https://www.ncbi.nlm.nih.gov/pubmed/37442994
http://dx.doi.org/10.1186/s12916-023-02904-9

Ejemplares similares